| The purinergic P2X7 receptor as a potential drug target to combat neuroinflammation in neurodegenerative diseases F Calzaferri, C Ruiz‐Ruiz, AMG de Diego, R de Pascual, I Méndez‐López, ... Medicinal research reviews 40 (6), 2427-2465, 2020 | 64 | 2020 |
| P2X7 receptor antagonism as a potential therapy in amyotrophic lateral sclerosis C Ruiz-Ruiz, F Calzaferri, AG García Frontiers in molecular neuroscience 13, 93, 2020 | 34 | 2020 |
| Increased expression of the ATP‐gated P2X7 receptor reduces responsiveness to anti‐convulsants during status epilepticus in mice E Beamer, J Morgan, M Alves, A Menendez Mendez, G Morris, B Zimmer, ... British Journal of Pharmacology 179 (12), 2986-3006, 2022 | 32 | 2022 |
| Synthesis and pharmacological evaluation of novel non-nucleotide purine derivatives as P2X7 antagonists for the treatment of neuroinflammation F Calzaferri, P Narros-Fernandez, R De Pascual, AMG De Diego, A Nicke, ... Journal of Medicinal Chemistry 64 (4), 2272-2290, 2021 | 27 | 2021 |
| Dual role of the P2X7 receptor in dendritic outgrowth during physiological and pathological brain development P Mut-Arbona, L Huang, M Baranyi, P Tod, A Iring, F Calzaferri, ... Journal of Neuroscience 43 (7), 1125-1142, 2023 | 14 | 2023 |
| P2X7 receptor antagonism as a potential therapy in amyotrophic lateral sclerosis. Front Mol Neurosci. 2020; 13: 93 C Ruiz-Ruiz, F Calzaferri, AG García | 5 | |
| P2X7R and TNFR1 antagonism neuroprotects rodent retinal ganglion cells in a sepsis model KTR Ramírez, F Calzaferri, CDL Rios, M Vidal‐Sanz, M Agudo‐Barriuso Acta Ophthalmologica 100, 2022 | 1 | 2022 |
| 3-Halo-3-nitro-aza/thioflavanones: DNMT inhibitors with a two-site binding mode in the hDNMT3A catalytic pocket A Serhouni, F Calzaferri, Y Bessina, A van der Lee, PB Arimondo, ... Bioorganic & Medicinal Chemistry 118, 117988, 2025 | | 2025 |
| Les manipulations de l’épigénome N LUVIANO, F CALZAFERRI, M LOPEZ Épigénétique en écologie et évolution, 129, 2024 | | 2024 |
| Pharmacological evaluation of novel non-nucleotide purine derivatives as P2X7R antagonists for the treatment of neuroinflammation in traumatic brain injury I Valencia, A Pastor-Martínez, C Decouty-Pérez, A Lopez-Rodriguez, ... | | 2024 |
| Retinal response to systemic inflammation differs between sexes and neurons KT Rodríguez-Ramírez, M Norte-Muñoz, F Lucas-Ruiz, A Gallego-Ortega, ... Frontiers in Immunology 15, 1340013, 2024 | | 2024 |
| Human DNMT3A inhibitors are potential active epigenome modulators in invertebrates A Dellong, M Lopez, F Calzaferri, O Portela, N Luviano, JF Allienne, ... REID 2023, 2023 | | 2023 |
| Novel Purine Derivative ITH15004 Facilitates Exocytosis through a Mitochondrial Calcium-Mediated Mechanism R de Pascual, F Calzaferri, PC Gonzalo, R Serrano-Nieto, C de Los Rios, ... International Journal of Molecular Sciences 23 (1), 440, 2021 | | 2021 |
| The ATP-gated P2X7 receptor contributes to the development of drug-resistant status epilepticus in mice E Beamer, J Morgan, M Alves, AM Mendez, G Morris, B Zimmer, G Conte, ... Authorea Preprints, 2021 | | 2021 |
| Design, synthesis and pharmacological evaluation of novel blood-brain barrier-permeable non-nucleotide purine derivatives as P2X7 antagonists for the treatment of … F Calzaferri Universidad Autónoma de Madrid, 2021 | | 2021 |
| SOMA, un innovador sistema de liberación de medicamentos biológicos por vía oral F Calzaferri Actualidad en farmacología y terapéutica 17 (2), 84-85, 2019 | | 2019 |
| Epidiolex, un nuevo medicamento aprobado derivado de la Marihuana F Calzaferri Actualidad en farmacología y terapéutica 16 (4), 273-273, 2018 | | 2018 |
| Non-nucleoside DNA methyltransferase inhibitors as therapeutic compounds and pharmacological tools for epigenetic reprogramming in cancer F Calzaferri, D Pechalrieu, D Dauzonne, PB Arimondo, M Lopez ½ Journée SCF d’Avenir Jeudi 24 Juin 2021 de 14h00 à 17h30, 0 | | |
LUIS GANDIAUNIVERSIDAD AUTONOMA DE MADRID在 uam.es 的电子邮件经过验证
LUIS GANDIAUNIVERSIDAD AUTONOMA DE MADRID在 uam.es 的电子邮件经过验证